{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:02:02Z","timestamp":1769637722842,"version":"3.49.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Treatment with dopamine agonists has been associated with cardiopulmonary fibrotic reactions, predominantly in patients treated for Parkinson's disease. To our knowledge, these reactions have previously not been associated with low-dose cabergoline treatment for hyperprolactinaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A case of constrictive pericarditis in a patient treated with cabergoline for hyperprolactinaemia is presented. The patient has been treated at a county hospital and a university hospital in southern Sweden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 20-year-old woman with a 3-year history of amenorrhoea was referred to the department in 1992. From 2001 to 2005, she was given cabergoline, 0.5\u20131.5\u200amg\/week. In 2005 a pericardectomy was performed due to fibrotic, constrictive pericarditis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our present case suggests that constrictive pericarditis may develop even on low-dose cabergoline, which might indicate that this reaction, as opposed to valvular fibrosis, is not mediated by a 5-HT<jats:sub>2B<\/jats:sub> agonistic mechanism.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-07-0584","type":"journal-article","created":{"date-parts":[[2008,3,24]],"date-time":"2008-03-24T20:38:31Z","timestamp":1206391111000},"page":"583-585","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":9,"title":["A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia."],"prefix":"10.1093","volume":"158","author":[{"given":"Magnus","family":"L\u00f6ndahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Katzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"issue":"1","key":"1_23452459","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"8","key":"2_18260930","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1136\/hrt.2004.036236","volume":"90","author":"Townsend","year":"2004","journal-title":"Heart","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0769","issn-type":"print"},{"issue":"4","key":"3_10799862","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4065\/74.4.371","volume":"74","author":"Ling","year":"1999","journal-title":"Mayo Clinic Proceedings","ISSN":"https:\/\/id.crossref.org\/issn\/0025-6196","issn-type":"print"},{"issue":"12","key":"4_18504575","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/mds.20330","volume":"19","author":"Chaudhuri","year":"2004","journal-title":"Movement disorders : official journal of the Movement Disorder Society","ISSN":"https:\/\/id.crossref.org\/issn\/0885-3185","issn-type":"print"},{"issue":"1","key":"5_23452436","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"Roth","year":"2007","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"2","key":"6_22061314","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/00002826-200603000-00005","volume":"29","author":"Hofmann","year":"2006","journal-title":"Clinical neuropharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0362-5664","issn-type":"print"},{"issue":"5","key":"7_18801454","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","volume":"112","author":"Dhawan","year":"2005","journal-title":"Journal of neural transmission","ISSN":"https:\/\/id.crossref.org\/issn\/0300-9564","issn-type":"print"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/158\/4\/583.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/158\/4\/583.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:21:02Z","timestamp":1676391662000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/158\/4\/583\/6675978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":7,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje-07-0584","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}